Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2491
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorPEREIRA, Rosa Maria Rodrigues-
dc.contributor.authorCARVALHO, Jozelio Freire de-
dc.contributor.authorPAULA, Ana Patricia-
dc.contributor.authorZERBINI, Cristiano-
dc.contributor.authorDOMICIANO, Diogo S.-
dc.contributor.authorGONCALVES, Helenice-
dc.contributor.authorDANOWSKI, Jaime S.-
dc.contributor.authorMARQUES NETO, Joao F.-
dc.contributor.authorMENDONCA, Laura M. C.-
dc.contributor.authorBEZERRA, Mailze C.-
dc.contributor.authorTERRERI, Maria Teresa-
dc.contributor.authorIMAMURA, Marta-
dc.contributor.authorWEINGRILL, Pedro-
dc.contributor.authorPLAPLER, Perola G.-
dc.contributor.authorRADOMINSKI, Sebastiao-
dc.contributor.authorTOURINHO, Tatiana-
dc.contributor.authorSZEJNFELD, Vera L.-
dc.contributor.authorANDRADA, Nathalia C.-
dc.date.accessioned2013-10-02T19:18:49Z-
dc.date.available2013-10-02T19:18:49Z-
dc.date.issued2012-
dc.identifier.citationREVISTA BRASILEIRA DE REUMATOLOGIA, v.52, n.4, p.569-593, 2012-
dc.identifier.issn0482-5004-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2491-
dc.description.abstractGlucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating or already on GC. There are several recommendations on this topic elaborated by several international societies, but consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are based on the WHO Fracture Risk Assessment Tool (FRAX (R)) to evaluate the risk for each individual, and, thus, cannot be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis (GIO), based on the better available scientific evidence and/or expert experience. Method of evidence collection: The bibliographic review of scientific articles of this guideline was performed in the MEDLINE database. The search for evidence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glitcocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glitcocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D deficiency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder; Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 years), adolescence (13-18 years). Grade of recommendation and level of evidence: A) Data derived from more consistent experimental and observational studies; B) Data derived from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion without explicit critical appraisal, or based on consensus, physiological studies or animal models. Objective: To establish guidelines for the prevention and treatment of GIO.-
dc.description.abstractOs glicocorticoides (GC) são prescritos por praticamente todas as especialidades médicas, e cerca de 0,5% da população geral do Reino Unido utiliza esses medicamentos. Com o aumento da sobrevida dos pacientes com doenças reumatológicas, a morbidade secundária ao uso dessa medicação representa um aspecto importante que deve ser considerado no manejo de nossos pacientes. As incidências de fraturas vertebrais e não vertebrais são elevadas, variando de 30%–50% em pessoas que usam GC por mais de três meses. Assim, a osteoporose e as fraturas por fragilidade devem ser prevenidas e tratadas em todos os pacientes que iniciarão ou que já estejam em uso desses esteroides. Diversas recomendações elaboradas por várias sociedades internacionais têm sido descritas na literatura, porém não há consenso entre elas. Recentemente, o Americam College of Rheumatology publicou novas recomendações, porém elas são fundamentadas na FRAX ( WHO Fracture Risk Assessment Tool ) para analisar o risco de cada indivíduo e, dessa maneira, não podem ser completamente utilizadas pela população brasileira. Dessa forma, a Comissão de Osteoporose e Doenças Osteometabólicas da Sociedade Brasileira de Reumatologia, em conjunto com a Associação Médica Brasileira e a Associação Brasileira de Medicina Física e Reabilitação, implementou as diretrizes brasileiras de osteoporose induzida por glicocorticoide (OPIG), baseando-se na melhor evidência cientí fi ca disponível e/ou experiência de experts . Descrição do método de coleta de evidência: A revisão bibliográ fi ca de artigos cientí fi cos desta diretriz foi realizada na base de dados MEDLINE. A busca de evidência partiu de cenários clínicos reais, e utilizou as seguintes palavras-chave (MeSH terms): Osteoporosis, Osteoporosis/chemi- cally induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/ prevention&control, Calcium, Vitamin D, Vitamin D de fi ciency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6–12 anos), adolescence (13–18 anos). Grau de recomendação e força de evidência: A) Estudos experimentais e observacionais de melhor consistência; B) Estudos experimentais e observacionais de menor consistência; C) Relatos de casos (estudos não controlados); D) Opinião desprovida de avaliação crítica, com base em consensos, estudos fisiológicos ou modelos animais. Objetivo: Estabelecer as diretrizes para a prevenção e o tratamento da OPIG.-
dc.description.sponsorshipNovartis-
dc.description.sponsorshipEly Lilly-
dc.description.sponsorshipServier-
dc.description.sponsorshipPfizer-
dc.description.sponsorshipSanofi-Aventis-
dc.description.sponsorshipRoche-
dc.description.sponsorshipMSD-
dc.description.sponsorshipAmgen-
dc.description.sponsorshipAche-
dc.description.sponsorshipEurofarma-
dc.description.sponsorshipAbbott-
dc.description.sponsorshipSEM-
dc.description.sponsorshipGSK-
dc.description.sponsorshipZodiac-
dc.language.isoeng-
dc.language.isopor-
dc.publisherELSEVIER SCIENCE INC-
dc.relation.ispartofRevista Brasileira de Reumatologia-
dc.rightsopenAccess-
dc.subjecttreatment-
dc.subjectosteoporosis-
dc.subjectglucocorticoid-
dc.subjecttratamento-
dc.subjectosteoporose-
dc.subjectglicocorticoide-
dc.subject.otherbone-mineral density-
dc.subject.othercorticosteroid-induced osteoporosis-
dc.subject.otherjuvenile idiopathic arthritis-
dc.subject.otherrandomized controlled-trial-
dc.subject.othervertebral fracture-
dc.subject.otherdouble-blind-
dc.subject.otherpostmenopausal women-
dc.subject.otherphysical-activity-
dc.subject.otherzoledronic acid-
dc.subject.otherclinical-densitometry-
dc.titleGuidelines for the prevention and treatment of glucocorticoid-induced osteoporosis-
dc.title.alternativeDiretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide-
dc.typearticle-
dc.rights.holderCopyright ELSEVIER SCIENCE INC-
dc.identifier.doi10.1590/S0482-50042012000400009-
dc.identifier.pmid22885424-
dc.subject.wosRheumatology-
dc.type.categoryreview-
dc.type.versionpublishedVersion-
hcfmusp.author.externalPAULA, Ana Patricia:OPI HCFMUSP-
hcfmusp.author.externalZERBINI, Cristiano:OPI HCFMUSP-
hcfmusp.author.externalGONCALVES, Helenice:OPI HCFMUSP-
hcfmusp.author.externalDANOWSKI, Jaime S.:OPI HCFMUSP-
hcfmusp.author.externalMARQUES NETO, Joao F.:OPI HCFMUSP-
hcfmusp.author.externalMENDONCA, Laura M. C.:OPI HCFMUSP-
hcfmusp.author.externalBEZERRA, Mailze C.:OPI HCFMUSP-
hcfmusp.author.externalTERRERI, Maria Teresa:OPI HCFMUSP-
hcfmusp.author.externalWEINGRILL, Pedro:OPI HCFMUSP-
hcfmusp.author.externalRADOMINSKI, Sebastiao:OPI HCFMUSP-
hcfmusp.author.externalTOURINHO, Tatiana:OPI HCFMUSP-
hcfmusp.author.externalSZEJNFELD, Vera L.:OPI HCFMUSP-
hcfmusp.author.externalANDRADA, Nathalia C.:OPI HCFMUSP-
hcfmusp.description.beginpage569-
hcfmusp.description.endpage593-
hcfmusp.description.issue4-
hcfmusp.description.volume52-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-84866492201-
hcfmusp.origem.idWOS:000307680400009-
hcfmusp.origem.idSCIELO:S0482-50042012000400009-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAdachi JD, 2001, ARTHRITIS RHEUM, V44, P202, DOI 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W-
hcfmusp.relation.referenceAdachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603-
hcfmusp.relation.referenceAdler RA, 2003, ARCH INTERN MED, V163, P2619, DOI 10.1001/archinte.163.21.2619-
hcfmusp.relation.referenceAmerican College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis, 2001, ARTHRITIS RHEUM, V44, P1496-
hcfmusp.relation.referenceAngeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005-
hcfmusp.relation.referenceBaim S, 2008, J CLIN DENSITOM, V11, P75, DOI 10.1016/j.jocd.2007.12.007-
hcfmusp.relation.referenceBatch JA, 2003, J PAEDIATR CHILD H, V39, P88, DOI 10.1046/j.1440-1754.2003.00083.x-
hcfmusp.relation.referenceBianchi ML, 2005, BEST PRACT RES CL RH, V19, P991, DOI 10.1016/j.berh.2005.06.006-
hcfmusp.relation.referenceBianchi ML, 2000, ARTHRITIS RHEUM, V43, P1960, DOI 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J-
hcfmusp.relation.referenceBlack DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312-
hcfmusp.relation.referenceBLODGETT FM, 1956, NEW ENGL J MED, V254, P636, DOI 10.1056/NEJM195604052541402-
hcfmusp.relation.referenceBraith RW, 2003, J HEART LUNG TRANSPL, V22, P1082, DOI 10.1016/S1053-2498(02)01184-1-
hcfmusp.relation.referenceBrown JJ, 2005, J PAEDIATR CHILD H, V41, P580, DOI 10.1111/j.1440-1754.2005.00720.x-
hcfmusp.relation.referenceBuckley LM, 1996, ANN INTERN MED, V125, P961-
hcfmusp.relation.referenceCanalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395-
hcfmusp.relation.referenceChan B, 2006, J CLIN ENDOCR METAB, V91, P2017, DOI 10.1210/jc.2005-2548-
hcfmusp.relation.referenceCohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K-
hcfmusp.relation.referenceCruse LM, 2006, JCR-J CLIN RHEUMATOL, V12, P221, DOI 10.1097/01.rhu.0000242778.65766.22-
hcfmusp.relation.referencede Jong Z, 2004, ARTHRITIS RHEUM, V50, P1066, DOI 10.1002/art.20117-
hcfmusp.relation.referencede Nijs RNJ, 2006, NEW ENGL J MED, V355, P675, DOI 10.1056/NEJMoa053569-
hcfmusp.relation.referencede Nijs RNJ, 2004, OSTEOPOROSIS INT, V15, P589, DOI 10.1007/s00198-004-1614-5-
hcfmusp.relation.referenceDevogelaer JP, 2006, OSTEOPOROSIS INT, V17, P8, DOI 10.1007/s00198-005-2032-z-
hcfmusp.relation.referenceDjokanovic Nada, 2008, J Obstet Gynaecol Can, V30, P1146-
hcfmusp.relation.referenceDUNLOP DJ, 1990, ANN RHEUM DIS, V49, P955, DOI 10.1136/ard.49.11.955-a-
hcfmusp.relation.referenceKorkor Adel B, 2009, WMJ, V108, P181-
hcfmusp.relation.referenceEnsrud KE, 2007, J GERONTOL A-BIOL, V62, P744-
hcfmusp.relation.referenceFranchimont N, 2003, AUTOIMMUN REV, V2, P224, DOI 10.1016/S1568-9972(03)00056-9-
hcfmusp.relation.referenceGeusens PP, 2004, ANN RHEUM DIS, V63, P324, DOI 10.1136/ard.2003.008060-
hcfmusp.relation.referenceGillespie LD, 2009, COCHRANE DB SYST REV, V15-
hcfmusp.relation.referenceGrossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295-
hcfmusp.relation.referenceHodgson Stephen F, 2003, Endocr Pract, V9, P544-
hcfmusp.relation.referenceHOMIK J, 2000, COCHRANE DB SYST REV-
hcfmusp.relation.referenceIllidge T M, 1996, Clin Oncol (R Coll Radiol), V8, P257, DOI 10.1016/S0936-6555(05)80667-3-
hcfmusp.relation.referenceJENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602-
hcfmusp.relation.referenceKaji H, 2006, ENDOCR J, V53, P27, DOI 10.1507/endocrj.53.27-
hcfmusp.relation.referenceKohrt WM, 2004, MED SCI SPORT EXER, V36, P1985, DOI 10.1249/01.MSS.0000142662.21767.58-
hcfmusp.relation.referenceLangdahl BL, 2009, OSTEOPOROSIS INT, V20, P2095, DOI 10.1007/s00198-009-0917-y-
hcfmusp.relation.referenceLau AN, 2010, THER CLIN RISK MANAG, V6, P497, DOI 10.2147/TCRM.S7776-
hcfmusp.relation.referenceLeufkens HG, 2000, J BONE MIN RES, V15-
hcfmusp.relation.referenceLevy S, 2009, BONE, V44, P428, DOI 10.1016/j.bone.2008.11.001-
hcfmusp.relation.referenceLewiecki EM, 2008, BONE, V43, P1115, DOI 10.1016/j.bone.2008.08.106-
hcfmusp.relation.referenceLyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941-
hcfmusp.relation.referenceMaricic Michael, 2005, Curr Osteoporos Rep, V3, P25, DOI 10.1007/s11914-005-0024-8-
hcfmusp.relation.referenceMaricic M, 2004, J CLIN DENSITOM, V7, P359, DOI 10.1385/JCD:7:4:359-
hcfmusp.relation.referenceMINSKER DH, 1993, TOXICOL APPL PHARM, V121, P217, DOI 10.1006/taap.1993.1148-
hcfmusp.relation.referenceMorin S, 2009, OSTEOPOROSIS INT, V20, P363, DOI 10.1007/s00198-008-0688-x-
hcfmusp.relation.referenceMunns CFJ, 2004, J BONE MINER RES, V19, P1742, DOI 10.1359/JBMR.040711-
hcfmusp.relation.referenceNational Osteoporosis Society & Royal College of Physicians guidelines working group for Bone and Tooth Society, 2002, GLUC IND OST GUID PR-
hcfmusp.relation.referenceNawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774-004-0596-x-
hcfmusp.relation.referenceNewman ED, 2006, OSTEOPOROSIS INT, V17, P1428, DOI 10.1007/s00198-006-0149-3-
hcfmusp.relation.referenceNoguera A, 2003, J PEDIATR ENDOCR MET, V16, P529-
hcfmusp.relation.referenceOkada Y, 2008, J RHEUMATOL, V35, P2249, DOI 10.3899/jrheum.080168-
hcfmusp.relation.referenceOrnoy A, 2006, REPROD TOXICOL, V22, P578, DOI 10.1016/j.reprotox.2006.05.009-
hcfmusp.relation.referencePatlas N, 1999, TERATOLOGY, V60, P68, DOI 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H-
hcfmusp.relation.referencePongchaiyakul C, 2004, OSTEOPOROSIS INT, V15, P807, DOI 10.1007/s00198-004-1613-6-
hcfmusp.relation.referencePoulos P, 2000, CLIN EXP RHEUMAT S21, V18, pS79-
hcfmusp.relation.referenceReid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140-6736(09)60250-6-
hcfmusp.relation.referenceReid DM, 2001, CALCIFIED TISSUE INT, V69, P242, DOI 10.1007/s00223-001-1060-8-
hcfmusp.relation.referenceRichy F, 2004, OSTEOPOROSIS INT, V15, P301, DOI 10.1007/s00198-003-1570-5-
hcfmusp.relation.referenceRietbrock S, 2009, QJM-INT J MED, V102, P35, DOI 10.1093/qjmed/hcn130-
hcfmusp.relation.referenceRinge JD, 2004, RHEUMATOL INT, V24, P63, DOI 10.1007/s00296-003-0361-9-
hcfmusp.relation.referenceRoth J, 2007, Z RHEUMATOL, V66, P434, DOI 10.1007/s00393-007-0174-4-
hcfmusp.relation.referenceRudge S, 2005, RHEUMATOLOGY, V44, P813, DOI 10.1093/rheumatology/keh538-
hcfmusp.relation.referenceSaag KG, 2009, ARTHRITIS RHEUM, V60, P3346, DOI 10.1002/art.24879-
hcfmusp.relation.referenceSaag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408-
hcfmusp.relation.referenceSaag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502-
hcfmusp.relation.referenceSambrook P, 2000, J BONE MINER RES, V15, P1818, DOI 10.1359/jbmr.2000.15.9.1818-
hcfmusp.relation.referenceSAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404-
hcfmusp.relation.referenceSchmitt NM, 2009, MATURITAS, V63, P34, DOI 10.1016/j.maturitas.2009.03.002-
hcfmusp.relation.referenceTeucher B, 2008, J BONE MINER RES, V23, P1477, DOI [10.1359/jbmr.080408, 10.1359/JBMR.080408]-
hcfmusp.relation.referenceThornton J, 2006, ARCH DIS CHILD, V91, P753, DOI 10.1136/adc.2006.093997-
hcfmusp.relation.referenceVan Staa T P, 2005, J Bone Miner Res, V20, P1487-
hcfmusp.relation.referenceVan Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283-
hcfmusp.relation.referenceVan Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913-
hcfmusp.relation.referencevan Staa TP, 2002, OSTEOPOROSIS INT, V13, P777-
hcfmusp.relation.referenceVARONOS S, 1987, CALCIFIED TISSUE INT, V41, P75, DOI 10.1007/BF02555248-
hcfmusp.relation.referenceWallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146-
hcfmusp.relation.referenceWalsh LJ, 1996, BRIT MED J, V313, P344-
hcfmusp.relation.referenceWinzenberg T, 2006, BMC PUBLIC HEALTH, P6-
hcfmusp.relation.referenceYARRINGTON JT, 1976, AM J PATHOL, V83, P569-
hcfmusp.relation.referenceYeap SS, 2008, J RHEUMATOL, V35, P2344, DOI 10.3899/jrheum.080634-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipAbbott-
hcfmusp.remissive.sponsorshipLilly-
hcfmusp.remissive.sponsorshipNovartis-
hcfmusp.remissive.sponsorshipPfizer-
hcfmusp.remissive.sponsorshipRoche-
hcfmusp.remissive.sponsorshipSanofi-Aventis-
hcfmusp.remissive.sponsorshipServier-
hcfmusp.citation.scopus61-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/IOT
Instituto de Ortopedia e Traumatologia - HC/IOT

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/41
LIM/41 - Laboratório de Investigação Médica do Sistema Músculoesquelético


Files in This Item:
File Description SizeFormat 
art_PEREIRA_Guidelines_for_the_prevention_and_treatment_of_glucocorticoid_2012_eng.PDFpublishedVersion (English)695.7 kBAdobe PDFThumbnail
View/Open
art_PEREIRA_Guidelines_for_the_prevention_and_treatment_of_glucocorticoid_2012_por.PDFpublishedVersion (Portuguese)681.53 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.